Form 4: Surrozen CFO Charles O. Williams Reports Stock Transactions

Surrozen's CFO, Charles O. Williams, executed transactions involving the company's common stock, including the vesting of restricted stock units and a sale to cover withholding taxes.

Summary

• Charles O. Williams, CFO and COO of Surrozen, Inc., reported transactions involving the company's common stock.
• On January 2, 2025, 3,500 restricted stock units (RSUs) vested and were settled in shares of common stock.
• Following the vesting, Mr. Williams sold 1,181 shares on January 3, 2025, at a price of $17.37 per share.
• The sale was to cover withholding taxes related to the vesting of the RSUs.
• Mr. Williams also owns 400 shares purchased on December 13, 2024, at $5.67 per share through the company's Employee Stock Purchase Plan.
• After these transactions, Mr. Williams beneficially owns 8,982 shares of Surrozen common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and expected, with no indication of positive or negative implications for the company's performance. The sale of shares by an insider is a slight negative, but it is for tax purposes.

Positives

• The vesting of RSUs indicates that performance milestones were likely met.
• The employee stock purchase plan allows employees to acquire shares at a discount, aligning their interests with the company's success.

Negatives

• The sale of shares by the CFO, even for tax purposes, could be perceived negatively by some investors.

Risks

• Sales of shares by insiders, even for tax purposes, can sometimes create short-term downward pressure on the stock price.
• The market may interpret insider sales as a lack of confidence in the company's future prospects, although this sale was for tax obligations.

Industry Context

This is a routine filing related to insider transactions and is common for publicly traded companies. It does not indicate any specific trend in the biotech industry.

Comparison to Industry Standards

• Insider transactions are a normal part of the operations of publicly traded companies, particularly in the biotech sector where stock-based compensation is common.
• Companies like Amgen, Gilead, and Regeneron also have similar filings related to their executives' stock transactions.
• The sale of shares to cover taxes is a standard practice and does not indicate any unusual activity.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an insider, but this is a common occurrence.
• Employees who participate in the stock purchase plan benefit from the discounted share price.

Key Dates

Keywords

Surrozen, insider trading, Form 4, stock transaction, restricted stock units, RSU, employee stock purchase plan, CFO, Charles O. Williams, share sale